Drug Profile
Perflutren - Lantheus Medical Imaging
Alternative Names: Definity; DEFINITY RT; Definity Vial; DEFINITY® Room Temperature; DMP 115; Luminity; MRX-115; Perflutren (PEG); Perflutren Lipid Microsphere; YM 454Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator ImaRx Therapeutics
- Developer Astellas Pharma; Lantheus Medical Imaging
- Class Contrast media; Diagnostic agents; Fluorocarbons
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cardiovascular disorders
- No development reported Kidney disorders; Liver disorders
Most Recent Events
- 26 Sep 2023 Phase-III clinical trials in Cardiovascular disorders (In children, Diagnosis) (IV) before September 2023 (Lantheus Medical Imaging pipeline September 2023)
- 28 Jun 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders(Diagnosis) in China (IV, Injection)
- 28 Jun 2021 No recent reports of development identified for clinical-Phase-Unknown development in Kidney-disorders(Diagnosis) in China (IV, Injection)